At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
MCI-186drug
Likely dose
MCI-186 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
In Brief
A Phase 1 clinical trial evaluating MCI-186 for Severe Hepatic Impairment and Healthy. Completed, enrolled 12 participants across 3 sites in 3 countries.
Detailed Summary
This is an open-label, single-dose study in male and female subjects with severe hepatic impairment and in male and female subjects with normal hepatic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hepatic Impairment, Healthy
CountriesCzechia, Hungary, Slovakia
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 10, 2018
Enrollment StartNov 6, 2018
Primary CompletionMar 25, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.8 years ago
Interventions
MCI-186drug
30 mg MCI-186 will be administered intravenously over 60 minutes.